• OPA Welcomes Government Support in Managing 30-days' Supply Limits
• OPA Supports Teva Canada in Mitigation of Salbutamol Shortages
• Updated: COVID-19 Resources and Tool
• Health Canada Toolkit: COVID-19 and Substance Use
• Mental Health Support for Frontline Staff
• NIHB New Listing and Dispensing Update
• WHO Academy App for Healthcare Providers

• Ask the Customer Experience and Administration Team
• Easier Process to Order PPE from RONCO Announced
• Reminder: Call for Resolutions

• Methadone, Buprenorphine and the Community Complimentary Live Webinar Series

• Store Risk Prevention Tips

• DDD Notice No. 20088 Posted May 13, 2020 Notice: Making Changes to the Trillium Drug Program in Response to COVID-19
• DDD Notice No. 20087 Posted May 13, 2020 Executive Officer Notice: Regulatory Amendments to Ontario Drug Benefit Program Co-payments

• Importation of Spanish-Labelled Salbutamol Aldo-Union inhalers due to Shortage of Canadian-Labelled Salbutamol
• Importation of Fresenius Propoven 2% due to Shortage of Canadian Labelled Propofol Injection 1% Products
• Important Safety Information - Importation of Teva UK-Labelled Salamol CFC-Free (Salbutamol Sulfate) Inhaler due to Shortage

• OCP Consultation on Expanding Scope of Practice: Pharmacist Prescribing for Minor Ailments
• Updated: COVID-19 Case Definition and Reference Document for Symptoms
• Managing Stress When Our World Has Come to a Halt: Free Webinar from PharmacyU
• COVID-19 Drug Evidence Initiative (CDEI)
• Nursing Week: May 11 - 17, 2020

• Ask the Practice Support Network
• New Pricing for Personal Protective Equipment (PPE) From RONCO
• ICYMI: OPA’s Partnership with Relief Buddy Continues. No Fees Until June 2020!

• Pandemic Tips: Medication Renewal

• What to Consider Before Selling or Buying a Pharmacy
• OPA Store Insurance Renewal 2020 - 2021

• DDD Notice No. 20086 posted May 6, 2020 Prescription Forgery Alert

• Important Safety Information for Certain Respirator Masks
• Unauthorized Test Kits Claiming to Diagnose or Detect COVID-19 Put Your Health at Risk
• Importation of US-Labelled Ketamine Hydrochloride for Injection due to Potential Shortage of Canadian-Labelled Ketamine
• Protect yourself and your family from poisonings: always read and follow the label directions when using hand sanitizers, disinfectants, household cleaning products and bleaches

• Pharmcovid19 #PharmacistsOnTheFrontline
• COVID-19 OPA advocacy web page
• Updated: COVID-19 pharmacy signage
• Updated: Return to work guidance tool
• Mental health resources from Canadian Foundation for Pharmacy and Therappx
• ICYMI: OPA's position on pandemic pay for publicly-paid pharmacy professionals

• Ask the Customer Experience and Administration Team
• OPA’s Partnership with Relief Buddy Continues. No Fees Until June 2020!

• Pandemic Tips: Opioid Agonist Therapy

• Get Your Reduced Driving Refund
• OPA Store Insurance Renewal 2020 - 2021

• DDD Notice No. 20085 Posted May 5, 2020 Prescription Forgery Alert
• DDD Notice No. 20084 Posted May 1, 2020 Executive Officer Notice: Proposed Regulatory Amendments to Ontario Drug Benefit (ODB) Program Co-payments and Dispensing Fees
• DDD Notice No. 20083 Posted May 1, 2020 Proposed Regulatory Amendments related to the Trillium Drug Program Deductible
• DDD Notice No. 20081 Posted April 29, 2020 Executive Officer Notice: Brand Reference Price Regulations Amendment

• Axid (Nizatidine) Drug Recalled Due to Presence of NDMA
• Clinical Trial Looking at the Potential Use of Convalescent Plasma to Treat COVID-19
• Health Product InfoWatch - April 2020
• Importation of US-Labelled QUELICIN (Succinylcholine Chloride Injection) and US-Labelled Rocuronium Bromide Injection Due to Shortage of Canadian-Labelled Products and Importation of US-Labelled • • Pancuronium Bromide Injection and US-Labelled Vecuronium Bromide for Injection Due to Shortage of Neuromuscular Blocker Products

• Third-party Payor Tools on Standard Refill Policies and COVID-19 Policy Exceptions
• OPA in the News: Pharmacists are the other frontline health workers (healthing.ca) April 14, 2020, Lisa Machado
• An Open Letter to the Patients of Ontario Pharmacists
• Pharmacists' Matters - Episode 2
• Guidance on Use of PPE for ANY Regulated Healthcare Professionals in Hospitals/LTCs/Retirement Homes (Directive #5)
• From the College: Guidance on the Controlled Drugs and Substances Act (CDSA) Subsection 56(1) Exemption
• Information on Non-insured Health Benefits (NIHB)
• Province Developing New Health Data Platform to Help Defeat COVID-19
• Ontario Significantly Expanding COVID-19 Testing
• Pharmacy5in5 Quiz: How to Provide Video Consults During the COVID-19 Pandemic
• ICYMI: Pharmacist's Letter Canada: Coronavirus (COVID-19) Resource Hub

• Ask the Practice Support Network
• ICYMI: New OPA Partnership to Support COVID-19 Staffing

• New Pandemic Tips from OPA Course Instructors

• Are You Financially Exposed Due to Inadequate Store Insurance Coverage?

• DDD Notice No. 20069 Posted April 14, 2020 Prescription Forgery Alert
• DDD Notice No. 20068 Posted April 14, 2020 Prescription Forgery Alert

• Fraudulent and unauthorized N95 respirators may not protect consumers against COVID-19

• A Thank You to Pharmacy Professionals on National Caregiver and World Health Day
• Return-to-Work Visual for Pharmacy Professionals During COVID-19
• New OPA Partnership to Support COVID-19 Staffing
• Revised Process for Ordering PPE
• Ontario Government Launches Healthcare Workforce Matching Portal
• Council of Chief Medical Officers of Health Guidance on Use of Non-Medical Masks by the Public
• Deputy Minister Notice on Re-Use of PPE
• Importance of Naloxone During Pandemic
• Financial Assistance for Pharmacists During COVID-19
• Pharmacist's Letter Canada: Coronavirus (COVID-19) Resource Hub
• A Video Message from OPA EVP and Chief Pharmacy Officer, Allan Malek, to Ontario Patients on 30-day Limits

• Ask the Customer Experience and Administration Team
• Deadline Extended for OPA Awards Nomination

• New Pandemic Tips from OPA Course Instructors

• Returning to Practice to Support Pharmacy During the COVID-19 Pandemic
• OPA Store Insurance Renewal 2020 - 2021

• DDD Notice No. 20067 posted April 7, 2020 ODB FORMULARY – EDITION NO. 43, Summary of Changes – April 7, 2020
• DDD Notice No. 20066 posted April 7, 2020 Executive Officer Notice: Regulation Amendments to Private Label Products and Brand Reference Pricing Rules
• DDD Notice No. 20064 posted April 6, 2020 Prescription Forgery Alert
• DDD Notice No. 20061 posted April 1, 2020 Notice: Extending Submission Period for Electronic Drug Claim Reversals AND The Ontario Drug Programs Reference Manual, Revision #1
• DDD Notice No. 20060 posted April 1, 2020 Notice from the Executive Officer: Policy for Methadone Maintenance Treatment Reimbursement under the Ontario Drug Benefit Program

• Homemade Hand Sanitizers May Present Health Risks

• Updated: Pharmacist's Guide to Pandemic Preparedness
• Updated: COVID-19 Case Definition
• New Process for PPE Ordering Coming
• Emergency Child Care Services for Pharmacy Professionals
• OPA CEO Video Message to Pharmacy Professionals
• 30 Days' Supply Recommendation Video Explainer from CPhA
I• ndustry Webinar: Managing the Challenges of Operating a Health Services Business During COVID-19
• ICYMI: Pharmacists' Matters Launches Episode #1
• ICYMI: Ontario’s Action Plan: Responding to COVID-19

• Ask the Practice Support Network
• Nominations for OPA Awards Deadline Extended

• Canadian Diabetes Educator Exam Postponed

• Business Expense Disability Insurance

• DDD Notice No. 20058 posted Mar 30, 2020 Notice from the Executive Officer: Proposed Regulatory Amendments on Rules for Determining Brand Reference Prices
• DDD Notice No. 20057 posted Mar 30, 2020 EO Notice: Proposed amendments to the effective date of changes to allow Private Label Products to be funded under the Ontario Drug Benefit (ODB) Program and Designated as Interchangeable on the ODB Formulary
• DDD Notice No. 20056 posted March 30, 2020 EO Notice: Funding of Truxima (rituximab) under the Ontario Drug Benefit Program
• DDD Notice No. 20055 posted March 26, 2020 Notice: COVID-19 Related Drug Prescribing
• DDD Notice No. 20054 Posted March 25, 2020 Health Network System (HNS) and Narcotics Monitoring System (NMS) Outage Notification to Ontario Drug Programs Agencies

• Health Canada Important Safety Information on Methadone Treatment of Opioid Dependence and Potential Differences in Product Effect
• Certain Lots of Taro-Zoledronic acid injection drug, used for osteoporosis and Paget's disease, recalled due to potential presence of particulate matter
• Stockpiling drugs can lead to local shortages: Canadians urged not to buy more medication than usual during the COVID-19 pandemic
• Health products that make false or misleading claims to prevent, treat or cure COVID-19
• Health Product InfoWatch - March 2020

• A Joint Message to Ontario’s Doctors, Nurses, Nurse Practitioners and Pharmacists on Use of Hydroxychloroquine and Azithromycin
• Updated: Supplementary FAQs to the Notice of the Executive Officer issued Friday, March 20
• COVID-19 and Non-Insured Health Benefits Coverage
• Exemptions for Controlled Substances During COVID-19
• Protect Your Pharmacist Social Card
• Pharmacists' Matters Lauches Episode #1

• Ask the Customer Experience Administration Team
• GoodLife, OPA affinity partner, stepping up to help members through COVID-19

• OPA Store Insurance – Understanding Your Coverage During COVID-19

• DDD Notice No. 20053 posted March 24, 2020 ODB Formulary Edition No. 43, Summary of Changes – March 31, 2020
• DDD Notice No. 20051 posted March 20, 2020 EO Notice: Ontario Drug Benefit (ODB) Program Changes & Guidance for Dispensers during the COVID-19 Public Health Emergency

• No scientific evidence that ibuprofen worsens COVID-19 symptoms
• Expedited access to disinfectants, hand sanitizers and personal protective equipment to help limit the spread of COVID-19, as well as swabs for testing

• OPA's Pharmacist's Guide to Pandemic Preparedness
• OPA signage for entrances to pharmacy
• Updated Guidance for Pharmacies on COVID-19 from the Ministry of Health
• CPhA: COVID-19 and the responsible allocation of medications to patients
• Sharing your concerns on personal protective equipment
• Community pharmacy owners support Ontario patients during COVID-19
• OPA staff work remotely

• Methadone, Buprenorphine and the Community
• FREE Take-Home Naloxone at Community Pharmacies
• Board Certified Geriatric Pharmacist (BCGP) Preparation Course – Medication Therapy Management for Older Adults

• Ask the Practice Support Network

• What you need to know when it comes to your benefits

• DDD Notice No. 20050 posted March 17, 2020 Prescription Forgery Alert
• DDD Notice No. 20049 posted March 17, 2020 Prescription Forgery Alert
• DDD Notice No. 20048 posted March 13, 2020 EO Notice: Monitored Drugs List (MDL)

• Update on the rifampin drug shortage